Parkinson’s Disease Market to Grow to $7 Billion by 2033

The Parkinson’s disease (PD) market across the seven major markets (7MM) is forecast to grow at a compound annual growth rate (CAGR) of 7.6% from $3.4 billion in 2023 to $7 billion in 2033, according to GlobalData, a leading data and analytics company.

GlobalData’s latest report, Parkinson’s disease: Seven Market Drug Forecast and Market Analysis – Update, reveals that the growth will be driven by the anticipated launches of eight late-stage pipeline products during the forecast period.

GlobalData anticipates the launch of six new symptomatic treatments for PD. Pipeline assets that target the motor symptoms of PD include NeuroDerm’s ND-0612 (carbidopa + levodopa), AbbVie’s tavapadon, Pharma Two B’s P2B001, Cerevance’s solengepras, and PharmaTher Holdings’ Ketarx. In addition to the debilitating motor symptoms suffered by PD patients, an array of non-motor symptoms such as PD dementia and PD psychosis are also a recognized part of the disease. Anavex’s blarcamesine is in development for the treatment of PD dementia. GlobalData forecasts that the six new symptomatic treatments for PD will contribute sales of $1.6 billion in the 7MM by 2033.

Christie Wong, Managing Neurology Analyst at GlobalData, comments “PD therapy currently centers on symptomatic treatment.  The need for disease-modifying therapies (DMTs) is one of the greatest unmet needs in the PD space. Key opinion leaders (KOLs) interviewed by GlobalData agreed that if a product significantly slowed the progression of PD, it would have the potential to revolutionize the treatment of the disease.”

As α-synuclein aggregates play an important role in PD disease pathogenesis and neurodegeneration, this potentially neurotoxic protein is a key molecular target for DMTs. GlobalData anticipates the launch of two late-stage products that target α-synuclein during the forecast period; Roche’s prasinezumab and Annovis Bio’s buntanetap.

Wong adds “Both products have faced a series of hurdles that have slowed their drug development progress, having failed to reach the primary endpoint in their pivotal trials (prasinezumab and buntanetap). But sub-group analysis and data from exploratory endpoints show promise of disease-modifying properties.”

Buntanetap and prasinezumab are estimated to generate global sales of $390.2 million and $207.3 million by 2033, respectively. Furthermore, DMTs are expected to contribute 8.5% of the PD market by 2033.

R&D efforts for DMTs are also expanding into new treatment modalities with clinical trials of cell therapies. According to GlobalData’s Drug Database, there are currently 15 cell therapies in Phase I-III development for PD. BlueRock Therapeutics’ bemdaneprocel is the furthest progressed among the cell therapies. Since PD occurs due to the degeneration of the dopaminergic neurons, bemdaneprocel involves stereotactically transplanting dopaminergic neuronal progenitor stem cells directly into the posterior putamen of PD patients. This is hoped to arrest disease progression and improve both motor and non-motor symptoms.

Wong continues “Bemdaneprocel is currently in a Phase III development trial (exPDite-2) and if successful, it would offer a novel DMT to the PD market that will compete with the α-synuclein inhibitors.”

While the PD market is projected to grow during the forecast period across the 7MM, it will face some barriers that will curtail its growth. Potential barriers to growth of the global PD market include the loss of exclusivity of several key branded products that are expected to face patent and data exclusivity expiration.

Wong concludes “The loss of patent exclusivity will allow cheaper generics to enter the market. Nonetheless, the launches of the pipeline therapies including symptomatic and disease-modifying therapies will drive market growth.”

4,000 of the world’s largest companies, including over 70% of FTSE 100 and 60% of Fortune 100 companies, make more timely and better business decisions thanks to GlobalData’s unique data, expert analysis and innovative solutions, all in one platform. GlobalData’s mission is to help our clients decode the future to be more successful and innovative across a range of industries, including the healthcare, consumer, retail, financial, technology and professional services sectors. To gain access to our latest press releases: GlobalData Media Centre.